Integrated serum proteomics and autoantibody analyses reveal a biomarker signature predictive of flare during biologic tapering in rheumatoid arthritis
Authors' conclusion
These findings identify a promising protein biomarker signature associated with flare during biologic tapering in RA, supporting biomarker-guided risk stratification in treatment optimisation strategies.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in sustained remission enrolled in the OPTIBIO trial; baseline serum samplesdiscovery subset n=44
- Participants
- 194 patients
- Comparison
- Flare vs sustained remission during bDMARD tapering; combined biomarker model vs clinical model
- Primary endpoint
- Disease flare during follow-up
Methodological detailssecondary analysis of the OPTIBIO randomised trial, two-stage design, exploratory mass spectrometry discovery subset, ELISA validation, anti-cytokine autoantibody profiling
- Secondary analysis of the OPTIBIO randomised trial
- Two-stage design
- Exploratory mass spectrometry discovery subset
- ELISA validation
- Anti-cytokine autoantibody profiling
Primary result
As reported in the abstract
Further findings
Proteins differentially abundant between flare and remission (discovery subset, optimisation arm)
- Differentially abundant proteins
- 87
Predictive performance in prolonged remission (secondary exploratory subgroup)
- AUC
- 0.839
Original publication
Integrated serum proteomics and autoantibody analyses reveal a biomarker signature predictive of flare during biologic tapering in rheumatoid arthritis. RMD Open. Published 23 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →